A new, one-year, double-blind controlled clinical study shows that cacao-flavonoids and soy isoflavones can significantly improve biomarkers of CVD risk in postmenopausal women with type 2 diabetes.
The trial, conducted by Peter Curtis, et al, funded by a UK based Charity, Diabetes UK and supported by Frutarom, Israel, and Barry Callebaut, has been published in Diabetes Care.
The purpose of the study was to assess the effect of dietary flavonoids on cardiovascular disease (CVD) risk in postmenopausal women with type 2 diabetes on established statin and hypoglycemic therapy.
At the conclusion of this trial, the combined one-year intervention with flavan-3-ols and isoflavones resulted in a significant improvement in biomarkers of CVD risk in postmenopausal type 2 diabetic patients, compared to placebo.
This data highlights the additional benefit of dietary flavonoids to standard drug therapy in managing CVD risk in this group of patients, according to the researchers.
Mira Koppert, manager of the LifeLine brand extension at Frutarom, said: “We are incredibly happy with the new study results showing that the soy isoflavones in SoyLife, produced by Frutarom, in combination with cacao-flavonoids could help decrease CVD risk.
"We anticipate these outstanding findings will open new opportunities in marketing SoyLife to supplement makers and food processors and position it as the leading soy isoflavones source in the global market.”
- Nestlé accelerates research on diabetes 13 MAR 2012 | Health
- Dietary flavonoids to provide health benefits for diabetes 16 JAN 2012 | Food
- Douwe Egberts redesigns packaging to reflect UTZ certification
- GlaxoSmithKline repositions Revive from Lucozade to drive sales
- Rabobank identifies three forces driving the hybrid consumer trend